Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Prentiss Christopher B

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/15/2017

3. Issuer Name and Ticker or Trading Symbol

Adamas Pharmaceuticals Inc [ADMS]

(Last) (First) (Middle)

C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 750

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Accounting Officer /

(Street)

EMERYVILLE, CA 94608

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9905 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	4/20/2025	Common Stock	35000	$0.00	D
Stock Option (Right to Buy)	⁽³⁾	3/3/2026	Common Stock	18750	$0.00	D
Stock Option (Right to Buy)	⁽⁴⁾	2/20/2027	Common Stock	20625	$0.00	D

Explanation of Responses:
(1)	Includes 5,781 restricted stock units that vest over four years.
(2)	Twenty-five percent of the shares subject to the option vested and became exercisable on April 1, 2016, the remainder vest and become exercisable in equal monthly installments over the next three years for a total vesting period of four years.
(3)	The shares subject to the option vest and become exercisable in equal monthly installments on the 1st of every month over four years with the first vesting on April 1, 2016.
(4)	The shares subject to the option vest and become exercisable in equal monthly installments on the 1st of every month over four years with the first vesting on April 1, 2017.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Prentiss Christopher B C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608			Chief Accounting Officer

Signatures
/s/ Jennifer Rhodes		9/22/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.